• Home
    Chevron
  • News & Events
    Chevron
  • Adapting Medications for Addiction Treatment Programs in Response to COVID-19
July 10, 2020

Adapting Medications for Addiction Treatment Programs in Response to COVID-19

Type: News

Medications for addiction treatment (MAT) programs save millions of lives and are an integral component of harm reduction strategies to address problematic opioid use. In the last decade, states and localities have expanded access to MAT — including services in primary care settings — in response to rising opioid overdose deaths around the country. COVID-19 has not only exacerbated the need for MAT due to a potential rise in substance use, but has also created new roadblocks to the effective delivery of MAT services.

Through their work around the country, the Camden Coalition of Healthcare Providers has seen firsthand how a complex care approach to substance use treatment can yield positive results. This has been especially apparent while integrating MAT into primary care settings. Lessons from this work, are outlined in their toolkit, Medications for Addiction Treatment: Providing Best Practice Care in a Primary Care Setting, can inform efforts in the current COVID-19 environment.